Free

Short and Long-term Consequences of Cannabis Medicalization & Legalization

Event Information

Share this event

Date and Time

Location

Location

Lilly Biotechnology Center

10290 Campus Point Drive

San Diego, CA 92121

View Map

Event description

Description

6pm: Social hour/Light dinner

7pm: Seminar presentation

About the Speaker:

Professor Marilyn A. Huestis recently retired as a tenured senior investigator and Chief, Chemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse, National Institutes of Health, after 23 years of conducting controlled drug administration studies.

Her research program focused on discovering mechanisms of action of cannabinoid agonists and antagonists, effects of in utero drug exposure, oral fluid testing, driving under the influence of drugs, and the neurobiology and pharmacokinetics of novel psychoactive substances. Professor Huestis’ research also explored new medication targets for cannabis dependence, including oral tetrahydrocannabinol (THC), Sativex, a 1:1 ratio of tetrahydrocannabinol and cannabidiol. She has published 464 peer-reviewed manuscripts and book chapters and more than 500 abstracts were presented at national and international meetings. Professor Huestis received a bachelor's degree in biochemistry from Mount Holyoke College (cum laude), a master's degree in clinical chemistry from the University of New Mexico (with honors), and a doctoral degree in toxicology from the University of Maryland (with honors). Professor Huestis received a Doctor Honoris Causa from the Faculty of Medicine, University of Helsinki in Finland in 2010.

She currently serves on the Organization of Scientific Area Committee on Toxicology, World Anti-doping Agency’s Prohibited List Committee, Transportation Research Board Committee on Alcohol and Other Drugs, and the National Safety Council’s Alcohol, Drugs and Impairment Division Executive Board.

About the Presentation:

The endogenous cannabinoid system in all of our brains is involved in critical survival, cognitive and motor functions. We will explore these functions and how they are altered by cannabinoids present in cannabis. This is a period of great expansion in the use of cannabinoids as therapeutics; however, the number of placebo-controlled, randomized clinical trials documenting the effectiveness of cannabinoids in treating different diseases is low. In addition, there is a growing use of cannabis for non-medical use. The short and long term consequences of this increasing cannabinoid exposure include decreasing perception of risk of using the drug, increasing cannabis dependence and requests for treatment, increased driving under the influence of cannabis, and increased in utero, breastfeeding and passive cannabis exposure. Although ∆9-tetrahydrocannabinol in blood is measureable in the blood of occasional cannabis users for only hours, it can be measured in the blood of chronic frequent cannabis smokers for as long as 30 days. Markers of recent cannabis intake in blood are similar in both groups of cannabis users and may help distinguish recent use from residual THC excretion in chronic frequent users.

MEETING SPONSORS- Shimadzu, Thermo Fisher Scientific and Waters Corporation

Share with friends

Date and Time

Location

Lilly Biotechnology Center

10290 Campus Point Drive

San Diego, CA 92121

View Map

Save This Event

Event Saved